Triplet schedule of weekly 5-Fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding and phase II study

Oncology Reports

Volumn 23, Issue 6, 2010, Pages 1635-1640

  Morelli, M F ^b   Santomaggio, A ^a   Ricevuto, E ^a   Cannita, K ^a   De Galitiis, F ^b   Tudini, M ^a   Bruera, G ^a   Mancini, M ^a   Pelliccione, M ^a   Calista, F ^a   Guglielmi, F ^a   Martella, F ^a   Lanfiuti Baldi, P ^a   Porzio, G ^a   Russo, A ^d   Gebbia, N ^d   Iacobelli, S ^e   Marchetti, P ^b,c   Ficorella, Corrado ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

Author keywords

5 Fluorouracil; Advanced colorectal cancer; CPT 11; l OHP

Indexed keywords

FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DOSE CALCULATION; DRUG DOSE ESCALATION; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPOTENSION; LIVER METASTASIS; LIVER RESECTION; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; TREATMENT RESPONSE; VOMITING; AGED; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; DOSE RESPONSE; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; SECONDARY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77951706637     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000805     Document Type: Article

References (32)

1. Ficorella C, Morelli MF, Ricevuto E, Cannita K, Porzio G, Baldi PL, Cianci G, DI Rocco ZC, Natoli C, Tinari N, DE Galitiis F, Calista F and Marchetti P: Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. Br J Cancer 91: 618-620, 2004.
2. Ficorella C, Ricevuto E, Morelli MF, Morese R, Cannita K, Cianci G, Porzio G, Di Rocco ZC, De Galitiis F, De Tursi M, Tinari N, Iacobelli S and Marchetti P: Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: a dose-finding study. Oncol Rep 15: 1345-1350, 2006.
3. Lévi F: Chronopharmacology of anticancer agents. In: Handbook of Exeperimental Pharmacology: Physiology and Pharmacology of Biological Rhythms - cancer Chemotherapy. P.H. Redfern and B. Lemmer (eds). Springer-Verlag, Berlin pp299-301, 1997.
4. Harris BE, Song R, Soong SJ and Diasio RB: Relationship between dihydropyrimidine dehidrogenase activity and plasma 5-fluorouracil levels with evidence for circadian varation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201, 1990.
5. Smaaland R, Abrahamsen JF, Svardal AM, et al: DNA cell cycle distrubution and glutathione (GSH) content according to circadian stage in bone marrow of cancer patients. Br J Cancer 66: 39-45, 1992.
6. O'Dwyer PJ, Manola J, Valone FH, et al: Fluorouracil modulation in colorectal cancer: lack of improvement with N-phosphonoacetyl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule-An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol 19: 2413-2421, 2001.
7. Leichman CG, Fleming TR, Muggia FM, et al: A Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 13: 1303-1311, 1995.
8. Schmoll H, Köhne C, Lorenz M, et al: Weekly 24-h infusion of high-dose 5-Fluorouracil with or without Folinic Acid vs bolus 5-FU/FA (NCCTG/Mayo) in advanced colorectal cancer: a randomized phase III study of the EORTC GITCCG and the AIO. Proc Am Soc Clin Oncol 10: 287, a935, 2000.
9. Levi F, Zidani R and Misset JL: Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 350: 681-686, 1997.
10. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J and Christian MC: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138-1147, 1997.
11. Bècourarn Y, Gamelin E, Coudert B, et al: Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil pretreated metastatic colorectal cancer patients. J Clin Oncol 19: 4195-4201, 2001.
12. Souglakos J, Mavroudis D, Kakolyris S, et al: Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol 20: 2651-2657, 2002.
13. Calvo E, Cortes J, Rodriguez J, et al: Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. Clin Colorectal Cancer 2: 104-110, 2002.
14. Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM and Goldberg RM: Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol 21: 3761-3769, 2003.
15. Garufi C, Bria E, Vanni B, et al: A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. Br J Cancer 89: 1870-1875, 2003.
16. Ychou M, Conroy T, Seitz JF, Gourgou S, Hua A, Mery-Mignard D and Kramar A: An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol 14: 481-489, 2003.
17. Cals L, Rixe O, Francois E, Favre R, Merad L, Deplanque G, Laadem A, Juin P, Bereder JM, Bernardini D and Herait P: Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Ann Oncol 15: 1018-1024, 2004.
18. Masi G, Allegrini G, Cupini S, et al: First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol 15: 1766-1772, 2004.
19. Gil-Delgado MA, Bastian G, Guinet F, Spano JP, Taillibert S, Rocher MA, Castaing D, Adam R, Urien S, Bismuth H and Khayat D: Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients. Am J Clin Oncol 27: 294-298, 2004.
20. Abad A, Massuti B, Gallego J, Yuste AL, Manzano JL, Carrato A, Anton A, Marfa X and Diaz-Rubio E; Spanish Cooperative Group for Gastrointestinal Tumor Therapy: Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors. Anticancer Drugs 15: 469-471, 2004.
21. Rosati G, Tucci A, Rinaldi A, et al: A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. Oncology 66: 371-378, 2004.
22. Aparicio J, Fernandez-Martos C, Vincent JM, Maestu I, Llorca C, Busquier I, Campos JM, Perez-Enguix D and Balcells M: FO LFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 5: 263-267, 2005.
23. Seium Y, Stupp R, Ruhstaller T, Gervaz P, Mentha G, Philippe M, Allal A, Trembleau C, Bauer J, Morant R and Roth AD: Oxaliplatin combined with irinotecan and 5-fluorouracil/ leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. Ann Oncol 16: 762-766, 2005.
24. Ferrari V, Valcamonico F, Amoroso V, Simoncini E, Vassalli L, Marpicati P, Rangoni G, Grisanti S, Pasinetti N and Marini G: An alternating rEgimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. Oncology 69: 283-289, 2005.
25. Martinez J, Martin C, Chacon M, Korbenfeld E, Bella S, Senna S, Richardet E, Coppola F, Bas C, Hidalgo J, Escobar E, Reale M, Smilovich AM and Wasserman E: Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. Am J Clin Oncol 29: 45-51, 2006.
26. Bonetti A, Zaninelli M, Durante E, Fraccon AP, Franceschi T, Pasini F, Zustovich F and Brienza S: Multiple-target chemotherapy (LV-modulated 5-FU bolus and continuous infusion, oxaliplatin, CPT- 11) in advanced 5-FU-refractory colorectal cancer: MTD definition and efficacy evaluation. A phase I-II study. Tumori 92: 389-395, 2006.
27. Comella P, Massidda B, Palmeri S, Putzu C, De Rosa V, Izzo F, Fiore F, Casaretti R and Sandomenico C: Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colo-rectal cancer. Anticancer Drugs 17: 985-992, 2006.
28. McWilliams RR, Goetz MP, Morlan BW, Salim M, Rowland KM, Krook JE, Ames MM and Erlichman C: Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/ leucovorin for metastatic colorectal cancer. Clin Colorectal Cancer 6: 516-521, 2007.
29. Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, Delpero JR, Rivoire M, Quénet F, Portier G and Nordlinger B: Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases Cancer Chemother Pharmacol 62: 195-201, 2007.
30. Abad A, Massutí B, Antón A, Vega M, Yuste AL, Marcuello E, Manzano JL, Alonso V, Carrato A, Martinez-Villacampa M, Tabernero J, Aranda E, Rivera F, Díaz-Rubio E and Therapy OB: Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. Acta Oncol 47: 1-7, 2007.
31. Souglakos J, Andrulakis N, Syrigos K, et al: FOLFOXIRI (folin acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folin acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94: 798-805, 2006.
32. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M and Masi G; Gruppo Oncologico Nord Ovest: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25: 1670-1676, 2007.